Pregnant Woman getting RSV Vaccine

Pfizer announces that infants are protected against severe illness by using an experimental RSV vaccine

Pfizer’s experimental RSV vaccine is safe for newborns for up to six months. The company released this statement Tuesday.

According to Pfizer, the vaccine was 82% effective in preventing severe respiratory syncytial viruses (RSV) in infants born to vaccinated mothers in phase 3. The vaccine was 70% effective against severe infections in the first six months.

Protection against RSV infections was less than 57% for the first 90 days, and 51% for the first six months.

These results were made public in a news release. They have not been published in any medical journals or reviewed by scientists outside of the lab.

Pfizer stated that it will submit data to the Food and Drug Administration before the end of this year. Albert Bourla, the CEO of Pfizer, stated Tuesday on a conference call with investors that he believes the vaccine will be available in late 2023 or early twenty24. A group of independent experts who are not part of the monitoring of the trial recommended that the company stop enrolling in the trial early due to the potential benefits of the vaccine.

According to Dr. Ofer Levi, who is the director of the Precision Vaccines Program at Boston Children’s Hospital, “the results sound very promising.”

He said that he could not draw any conclusions as the results were disclosed in a press

release and that he hadn’t seen all the data.

He said that he would love for the vaccine to be 100% effective. “But many vaccines fail to achieve that level, so this is an acceptable level of efficacy.”

About 7,400 women were included in the trial. They received either one dose of vaccine or a placebo in the second and third trimesters of their pregnancies. The babies were monitored for at least one full year after their birth.

Pfizer didn’t release any information about whether there was an increase in infant protection based on the time that the mother was vaccinated. According to Pfizer, the company expects that such data will be available once final results have been published in peer-reviewed journals.

The company published interim data in April that indicated that pregnant women who had received the vaccine were able to pass their protective antibodies on to their babies.

Levy pointed out that the babies may be acquiring RSV antibodies through their mothers rather than receiving them directly. This is also known as passive vaccination. The protection might not last as long and they could need another dose.

Pfizer stated in a statement it is not currently conducting an RSV vaccine study in infants. It stated that it will continue to assess babies born to vaccinated mothers for up to 24 months to ensure its ongoing analysis.

The trial results are coming amid an increase in RSV cases in children, which is contributing to a shortage of beds in children’s hospitals in the United States. Covid is also rising in flu cases at hospitals.

According to the Centers for Disease Control and Prevention, RSV is the most common cause of bronchiolitis and pneumonia in children aged 12 and older. There is no vaccine currently available. This virus causes hundreds of deaths and thousands of hospitalizations in children each year.

RSV, like many other respiratory infections in infants and children, can cause severe breathing problems. Children as young as two years old can experience difficulty breathing because of their smaller airways. This can lead to rapid accumulation of mucus in the throat, lungs, and throat.

RSV can put many babies in the hospital. “A vaccine that prevents severe illness 70% of the time up to the age of six months is very good,” Dr. Celine Gounder (a senior fellow at KFF and an infectious disease specialist) said.

She said that the vaccine’s effectiveness seems to diminish over time but, if it is timed properly, “it could save a lot of deaths and hospitalizations in this age group.”

Dr. William Schaffner at Vanderbilt University Medical Center is an infectious disease expert. He said he could “imagine the thousands that won’t have to endure the agony of having their baby admitted” if there was a vaccine against RSV.

To help prevent illness in infants, several vaccines are recommended for pregnant women, including those against whooping cough, flu, and Covid.

Schaffner stated that Pfizer’s RSV vaccine may be “a significant step forward so we can attack the last really bad communicable diseases of the neonatal period.”

RSVpreF is a vaccine from Pfizer that uses the same technology as other vaccines such as those for hepatitis B or shingles. It targets the protein that the virus uses to enter human cells.

Pfizer is also testing the vaccine on older adults who are at higher risk of RSV infection. In August, Pfizer reported positive results in that trial.

Pfizer previously stated that it plans to test its vaccine with younger people.

About The Author

Leave a Comment

Scroll to Top